07/10/2019 | Press release | Distributed by Public on 07/09/2019 22:50
June 27, 2019
A formulation containing a new base-ingredient*1 using adhesive technology of KM Transderm Ltd. (Headquarters: Kita-ku, Osaka; President: Haruki Tanabe; 'KM Transderm'), affiliate company of Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura; 'Kaneka'), was approved on March 13, as a partial change in the approved items of the manufacturing and marketing approval*2.
This formulation adopted the technology of KM Transderm as a partial change to the transdermal formulation*3 for the treatment of Alzheimer's Disease Dementia, sold as Rivastach® Patch and Exelon® Patch*4 (generic name: rivastigmine), marketed by Ono Pharmaeutical Co., Ltd. (Headquarters: Chuou-ku, Osaka; President: Gyo Sagara; 'ONO') and Novartis Pharma K.K. (Headquarters: Minato-ku, Tokyo; President: Kazunari Tsunaba; 'Novartis Pharma'), in order to improve the current formulation.
With the original formulation containing a silicone ingredient, adverse drug reactions have been reported related to dermal symptoms at the patch application site such as redness and pruritus, etc. Therefore, ONO, Novartis Pharma and KM Transderm have been collaborating for development of a formulation containing a new base-ingredient. The unique adhesive technology of KM Transderm, which is adopted for this approved formulation containing new base-ingredient, provides a skin-friendly adhesive base with excellent touch and having appropriate adhesiveness without using a tackifier, which was conventionally necessary in the synthetic rubber base.
Kaneka Group will keep contributing to the improvement of patients' QOL through the promotion of new product development in collaboration with pharmaceutical companies, utilizing our unique adhesive technologies.
＜General description of KM Transderm Ltd.＞
|Business:||Research, development of transdermal medical products|
|Capital:||300 million JPY|